Therapeutically, deferiprone, a BBB-permeating iron chelator traditionally used to treat peripheral iron overload [176], has been investigated for the treatment of aceruloplasminemia, pantothenate kinase–associated neurodegeneration, Friedreich’s ataxia, and PD, with preliminary evidence indicating that removal of excess iron from disease-implicated brain regions is accompanied by slowing of disease progression [177–181]. This evidence concerns the gene PANK1 and Friedreich ataxia.